Lilly asks platforms and payment processors to shut down retatrutide sellers

Eli Lilly said on Aug. 12, 2026 that it filed six new lawsuits against U.S. businesses selling black-market retatrutide, and publicly called on social media and e-commerce platforms, credit card companies, payment processors, and shipping and logistics carriers to stop handling the trade ^[2]. The move was highlighted the next day in STAT's biotech newsletter, which described a booming underground market for the drug ^[1].

Retatrutide is an investigational Lilly molecule in Phase 3 trials for obesity, type 2 diabetes and other related conditions ^[2]. No medicine containing retatrutide has been approved for human use by any regulatory agency anywhere in the world, and it cannot legally be sold to consumers ^[2]. That has not stopped sellers: Lilly says "medical spas," "wellness clinics" and self-described suppliers openly market retatrutide as a weight-loss "hack," often using product made by unregulated foreign manufacturers ^[2].

What Lilly says it has done

The company says it has referred more than 200 individuals and entities to the FDA, the U.S. Department of Justice, state attorneys general, law enforcement and professional licensing boards, and is working with regulators and customs authorities abroad ^[2]. It also says it has reported more than 14,000 websites, advertisements, social media posts and product listings that unlawfully market retatrutide across more than 100 countries to internet service providers, social platforms and e-commerce companies — but that "some continue to amplify misleading content to vulnerable consumers" ^[2].

The six new lawsuits name compounding pharmacies, medical spas and online sellers that, according to Lilly, falsely label their products "research-use only" when they are actually meant for people ^[2]. The cases are: Eli Lilly & Co. v. Aesthetic Envy Cosmetic Centers LLC (N.D. Cal.); v. Astra LLC, d/b/a Astra Peptides (W.D. Tex.); v. Legendary Peptides, LLC (E.D. Tex.); v. Striker Pharmacy, LLC (S.D. Tex.); v. Texas Peptides Inc. (W.D. Tex.); and v. Lone Star Peptide Co. (S.D. Tex.) ^[2]. The sources do not include responses from any of the named companies, and the outcome of the suits is not yet known.

"What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk," said David A. Hyman, M.D., Lilly's chief medical officer ^[2].

The regulatory backdrop

Lilly points to FDA statements that sales of unapproved retatrutide to consumers are illegal, that retatrutide cannot be lawfully compounded, and that so-called "research-use only" products "are of unknown quality and may be harmful to [consumers'] health" ^[2]. The FDA has also said that unapproved drugs sold for human use may pose significant risks and are illegal ^[2]. Lilly says regulators, customs agencies and law enforcement in other countries have raided clandestine manufacturing sites, seized shipments and arrested people involved ^[2].

Beyond platforms and payment companies, Lilly asked government authorities to prioritize cross-border enforcement, urged health care providers to raise awareness of the risks, and asked the public to report illegal retatrutide products to law enforcement, drug and pharmacy regulators, and the Lilly Answers Center at 1-800-LillyRx ^[2].

Why it matters for patients

Retatrutide is not the same situation as compounded semaglutide or tirzepatide, which at times moved through pharmacies during shortages. Retatrutide has never been approved anywhere, so there is no legal consumer version and, per the FDA as cited by Lilly, no lawful path to compound it ^[2]. Anything sold online as "reta" falls outside the system that verifies what is in a vial, how much is in it, and whether it was made under sterile conditions — which is why FDA calls research-use-only products of unknown quality ^[2].

The practical effect of Lilly's campaign, if platforms and payment processors respond, would be fewer listings, blocked checkouts and disrupted shipping for sellers. Whether those companies act, and how quickly, is not stated in the sources. People who have obtained these products may find suppliers disappear without notice, and there is no manufacturer safety monitoring or recall system behind them ^[2].

What happens next

The press release was issued Aug. 12, 2026 ^[2]; STAT covered it Aug. 13 ^[1]. No court dates, platform commitments or regulatory deadlines are given in the available sources.